trending Market Intelligence /marketintelligence/en/news-insights/trending/wushtof-gagt-swn4qdbmq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Innovus secures rights to allergy drug in US, Canada

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles


Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

Innovus secures rights to allergy drug in US, Canada

Innovus Pharmaceuticals Inc. secured a contract to market NTC Srl's Lertal tablets in U.S. and Canada under the AllerVarx brand name.

Innovus is making an undisclosed up-front payment to the Italian company and has agreed to make further milestone-related payments as a result of the agreement.

Lertal is used for the treatment of allergic rhinitis.